Amarillo Biosciences (OTCMKTS:AMAR) and Catabasis Pharmaceuticals (NASDAQ:CATB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.
This is a summary of recent ratings and price targets for Amarillo Biosciences and Catabasis Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Amarillo Biosciences and Catabasis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Amarillo Biosciences and Catabasis Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Amarillo Biosciences||$80,000.00||173.11||-$1.34 million||N/A||N/A|
|Catabasis Pharmaceuticals||$500,000.00||178.69||-$25.87 million||($5.12)||-1.52|
Amarillo Biosciences has higher earnings, but lower revenue than Catabasis Pharmaceuticals.
Institutional and Insider Ownership
21.6% of Catabasis Pharmaceuticals shares are held by institutional investors. 8.6% of Catabasis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Amarillo Biosciences has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Catabasis Pharmaceuticals has a beta of 1.72, suggesting that its share price is 72% more volatile than the S&P 500.
Catabasis Pharmaceuticals beats Amarillo Biosciences on 8 of the 10 factors compared between the two stocks.
Amarillo Biosciences Company Profile
Amarillo Biosciences, Inc. engages in the development of biologics for the treatment of human and animal diseases. The company owns or licenses five issued patents related to the low-dose oral delivery of interferon; and owns one issued patent on its dietary supplement, Maxisal. It focuses on research for the treatment of human disease indications primarily influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha. Amarillo Biosciences, Inc. was founded in 1984 and is based in Amarillo, Texas.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Amarillo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.